Human Immunodeficiency VirusImage: NIAIDThe Merck-funded STEP study, which used an adenoviral vector to deliver an HIV vaccine candidate, was halted in 2007 after the data suggested the vaccine ...
GlobalData on MSN1d
Boehringer and partners commence gene therapy trial for cystic fibrosisBoehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...
Since 1999, the Vector Development Laboratory has developed and implemented novel cellular and gene-based treatments for a variety of diseases. Gene transfer vectors provide investigators important ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback